Feedback
Settings

Settings

Goto Application

280,352 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,036
1.WO/2025/229086ADHESIVE COSMETIC COMPOUNDS AND USES THEREOF
WO - 06.11.2025
Int.Class A61Q 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
1Make-up preparations; Body powders; Preparations for removing make-up
 Appl.No PCT/EP2025/061882 Applicant SKINOSIVE Inventor AINIE, Lise
The present invention relates to a compound represented by the following formula (I): A[B-(C)v]w, wherein A is a cosmetic agent chosen among a skin care agent, a hair agent, a make-up agent, and a film-forming agent, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6000. It also relates to a composition comprising the same and uses thereof in cosmetic applications.
2.WO/2025/231081METHOD FOR SEPARATING OLIGONUCLEOTIDES
WO - 06.11.2025
Int.Class C07H 1/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
1Processes for the preparation of sugar derivatives
06Separation; Purification
 Appl.No PCT/US2025/027003 Applicant ALNYLAM PHARMACEUTICALS, INC. Inventor BROOKS, Joshua
The technology described herein relates generally to methods for purifying longer double-stranded and single-stranded oligonucleotides from shorter complementary or partially complementary oligonucleotide fragments.
3.WO/2025/228440MACROLIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 06.11.2025
Int.Class C07H 17/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
08Hetero rings containing eight or more ring members, e.g. erythromycins
 Appl.No PCT/CN2025/092612 Applicant EVOPOINT BIOSCIENCES CO., LTD. Inventor HU, Yonghan
The present invention relates to a macrolide compound, and a preparation method therefor and the use thereof. Specifically disclosed is a compound as shown in formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits a significant antibacterial activity, comprising the antibacterial activity against bacteria resistant to macrolide drugs such as azithromycin. The compound described herein has a low hepatotoxicity and superior safety compared to other macrolide compounds. The compound can be used for infectious diseases, etc.
4.WO/2025/230914NUCLEOTIDES WITH ENZYME-TRIGGERED SELF-IMMOLATIVE LINKERS FOR SEQUENCING BY SYNTHESIS
WO - 06.11.2025
Int.Class C07H 19/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
10with the saccharide radical being esterified by phosphoric or polyphosphoric acids
 Appl.No PCT/US2025/026687 Applicant ILLUMINA, INC. Inventor EMOND, Stephane
Embodiments of the present disclosure relate to nucleotide molecules having an enzymatically cleavable self-immolative linker group. Also provided herein are methods and kits for sequencing applications using such nucleotides.
5.WO/2025/231484METHODS OF PREPARING CAPPED MRNA WITH SITE-SPECIFIC MODIFICATIONS
WO - 06.11.2025
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/US2025/027793 Applicant GENSCRIPT USA INC. Inventor PI, Fengmei
A method for producing a site-specific modified capped recombinant RNA includes (a) obtaining a first RNA that is monophosphorylated at the 5' end and contains the site-specific modification, (b) reacting an activated capping compound of Formula (I), Formular (II), or Formula (III) with the 5' monophosphorylated first RNA obtained from (a) in the presence of a heteroaromatic compound, a metal salt, and a solvent, hereby producing a 5' capped first RNA, (c) obtaining a second RNA that is monophosphorylated at the 5' end, and (d) ligating the 3' end of the 5' capped first RNA obtained from (b) to the 5' end of the second RNA obtained from (c), thereby producing the site-specific modified capped recombinant RNA.
6.WO/2025/228348OLIGONUCLEOTIDE CONJUGATE AND USE THEREOF
WO - 06.11.2025
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/CN2025/091864 Applicant FRONTIER BIOTECHNOLOGIES INC. Inventor XIE, Dong
Provided are an oligonucleotide conjugate and use thereof. The oligonucleotide conjugate has a structure represented by formula II: C-(X) n-(B) k-A (formula II), wherein C is a group with relatively good lipid solubility; X represents an oligonucleotide for regulating gene expression levels, and n≥1; B represents a linking arm, and k≥1; A represents a group capable of reacting with a free active group of albumin to form a covalent bond. The oligonucleotide conjugate can have significantly higher in vivo oligonucleotide delivery efficiency and good in vivo stability and enables targeted delivery of the oligonucleotide to multiple extrahepatic tissues, such as hepatic tissue, renal tissue, and proximal convoluted tubule tissue, in vivo.
7.WO/2025/229953METHOD FOR PRODUCING OLIGONUCLEOTIDE
WO - 06.11.2025
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No PCT/JP2025/016225 Applicant SUMITOMO CHEMICAL COMPANY, LIMITED Inventor MIYAGAWA, Takuya
The purpose of the present invention is to provide a method for efficiently producing an oligonucleotide by a solid-phase synthesis approach. The present invention provides a method for producing an oligonucleotide by a solid phase synthesis approach, the method comprising a step for reacting an oligonucleotide in which a hydroxyl group at a chain extendable end is protected with a protective group that can be removed under acidic conditions and a deblocking solution to remove a protective group for a hydroxyl group at the chain extendable end, wherein the deblocking solution is a deblocking solution containing a base, an acid, and an aprotic solvent, and the base is a base having an acid dissociation constant (pKa) of a conjugate acid of 5-12, and an oligonucleotide in which the content ratio of the 2', 3'transfer body is a certain amount or less.
8.WO/2025/230581FC CONJUGATES AND USES THEREOF
WO - 06.11.2025
Int.Class C07H 19/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
 Appl.No PCT/US2025/011030 Applicant CIDARA THERAPEUTICS, INC. Inventor DAVARPANAH, Nicole
The disclosure provides conjugates including an Fc domain monomer or Fc domain covalently linked to a moiety that binds to or inhibits CD73. The disclosure also provides pharmaceutical compositions including such conjugates and uses of such conjugates in the treatment of cancer.
9.826044NUCLEOSIDE ANALOG FOR 5'-PHOSPHONATE MODIFICATION AND OLIGONUCLEOTIDE PREPARED THEREFROM
NZ - 31.10.2025
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
 Appl.No 826044 Applicant SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. Inventor SHU, Dongxu
The present invention relates to a nucleoside analog for 5' modification and an oligonucleotide prepared therefrom, and more particularly to a modification nucleoside and an analog thereof that can be incorporated into the end of an oligonucleotide, and may be incorporated into a double-stranded oligonucleotide (short interfering RNA) or single-stranded oligonucleotide (e.g., an antisense oligonucleotide). The oligonucleotide provided is expected to hybridize with a portion of a target RNA, thereby resulting in loss of the normal function of the target RNA.
10.826353LIPID-BASED CONJUGATES FOR SYSTEMIC, CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, AND OCULAR DELIVERY
NZ - 31.10.2025
Int.Class C07H 15/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
18Acyclic radicals, substituted by carbocyclic rings
 Appl.No 826353 Applicant SANEGENE BIO USA INC. Inventor WANG, Weimin
The present disclosure provides a Lipid-Based Lipid Agent being a compound of Formula : (I), (II), (III), or (IV): or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Based Lipid Agents and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.
# -